OBSEVA SA
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 15
- Market Cap
- -
- Website
- http://www.obseva.com
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 24
- Registration Number
- NCT03962049
- Locations
- 🇺🇸
Clinical Site, Orlando, Florida, United States
Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 33
- Registration Number
- NCT03961932
- Locations
- 🇺🇸
Clinical Site, Saint Paul, Minnesota, United States
Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 820
- Registration Number
- NCT03758885
- Locations
- 🇧🇪
Site 1004, Brussels, Belgium
🇨🇿Site 1109, Teplice, Czechia
🇵🇱Site 1706, Warsaw, Poland
PoC Study of OBE022 in Threatened Preterm Labour
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2021-06-07
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 115
- Registration Number
- NCT03369262
- Locations
- 🇮🇱
Rabin Medical Center, Fetal-Maternal Medicine, Helen Schneider's Hospital for Women, Petah tikva, Israel
🇮🇱Rambam Medical Center, Maternal Fetal Unit, Haifa, Israel
🇨🇿Gynekologicko-porodnická klinika Fakultnà nemocnice Brno, Brno, Czechia
Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 810
- Registration Number
- NCT03081208
- Locations
- ðŸ‡ðŸ‡º
Investigator ID 1604, Budapest, Hungary
🇧🇪Investigator ID 1003, Brussels, Belgium
ðŸ‡ðŸ‡ºInvestigator ID 1603, Pécs, Hungary
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 511
- Registration Number
- NCT03070951
- Locations
- 🇺🇸
Site reference ID 907, Houston, Texas, United States
🇧🇬Site reference ID 254, Sofia, Bulgaria
🇵🇱Site reference ID 505, Przemyśl, Poland
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 526
- Registration Number
- NCT03070899
- Locations
- 🇺🇸
Site reference ID 169, Dothan, Alabama, United States
🇺🇸Site reference ID 183, Dallas, Texas, United States
🇺🇸Site reference ID 109, Marrero, Louisiana, United States
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 328
- Registration Number
- NCT02778399
- Locations
- 🇺🇸
Site reference ID 418, Clearwater, Florida, United States
🇺🇸Site reference ID 471, Fall River, Massachusetts, United States
🇺🇸Site reference ID 462, Arcadia, California, United States
A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 10
- Registration Number
- NCT02326142
OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI
- Conditions
- Interventions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- ObsEva SA
- Target Recruit Count
- 247
- Registration Number
- NCT02310802